The significance of H19 overexpression for prognosis has also been assessed using The Cancer Genome Atlas database, which revealed that patients with endometrial/cervical cancer with H19 overexpression exhibited a reduced non-recurrence survival rate (hazard ratio (HR) = 2.261, P < 0.05) and a reduced overall survival rate (HR = 2.710, P < 0.05). This evidence concerns the gene H19 and cervical cancer.